Abstract
Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis. A 71-year-old woman experienced severe, acute esophagitis and severe stricture of the esophagus due to oral alendronate therapy. Unlike in previous cases, she had taken alendronate for 10 months before the onset of complications and the stricture proved resistant to dilation.
MeSH terms
-
Administration, Oral
-
Aged
-
Alendronate / administration & dosage
-
Alendronate / adverse effects*
-
Alendronate / therapeutic use
-
Dilatation
-
Esophageal Stenosis / chemically induced*
-
Esophageal Stenosis / diagnostic imaging*
-
Esophageal Stenosis / therapy
-
Esophagitis / chemically induced*
-
Esophagitis / diagnostic imaging*
-
Esophagitis / therapy
-
Female
-
Humans
-
Osteoporosis, Postmenopausal / drug therapy*
-
Radiography
-
Time Factors
-
Treatment Failure